- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06907225
Physiological Responses to Heat Stress During High-risk Events
Study Overview
Detailed Description
Exertional heat stroke (EHS) affects ~500 Military Personnel (MSMR, 2022) and over 100 Soldiers (Giersch et al, 2022) every year. EHS is the most severe form of exertional heat illness and can result in substantial, long-lasting organ damage and sometimes death. While some risk factors for EHS are known (Roberts et al, 2021), and the investigators have effective treatments available (Caldwell et al, 2022), EHS cases are not 100% preventable. Furthermore, it is not possible to investigate EHS directly in the laboratory, as safety criteria limit the core temperatures (Tcore) permitted. Therefore, clinicians must rely on prospective clinical investigations after normal training or events (e.g. road races, marathons, etc.).
Collecting data on Soldiers who experience heat stroke helps further our understanding of potential predisposing factors, recovery, and long-term health consequences. Specifically, biomarkers of cardiac, kidney, muscle, and liver damage can inform recovery and return-to-duty (RTD) decisions, but the direct effect of EHS on these systems remains largely unknown. Recent discussions with international colleagues, including the Surgeon General of the Israeli Defense Force, highlight the need for a prospective identification of those at greatest risk for EHS (BG Elon Glassberg, Surgeon General, Israeli Defense Force, personal communication, September 2022).
The proposed study will utilize a similar approach as that employed by a previous study (Kenney et al, 2012), that examined serum creatine kinase (CK) levels in a cohort of healthy basic trainees at Fort Moore. While 200 IU/L is commonly the upper limit of normal values, they found that trainees often had CK values exceeding 1,000 IU/L, which reflects chronic high-intensity physical training, rather than a pathological condition such as exertional rhabdomyolysis (ER). The findings from this paper have influenced the diagnostic criteria for ER, such that a CK level of 50x the upper limit of normal is often required for diagnosis. The effect, if any, of chronic/routine high intensity physical training on other biomarkers, such as creatinine for acute kidney injury and alanine aminotransferase/aspartate aminotransferase (ALT/AST) for liver injury, is unknown. Knowledge of the 'normal' physiological response to exercise-heat stress, as assessed by biomarkers of end-organ function, may potentially guide healthcare providers diagnostic decision-making process and prevent over-diagnosis of conditions. This in turn may result in shorter limited duty time and improved readiness. The proposed investigation will utilize a similar approach, but in a cohort relevant to EHS.
Whereas most EHS cases occur during ruck marches and timed runs (DeGroot et al, MSMR 2022), what is less clear is what represents a "positive" or adaptive physiological response to these high-risk events. One of the goals of the present project will be to identify biomarkers of "successful" exposure to high-risk events. These biomarkers would be present in individuals who successfully complete the events, but don't experience an exertional heat illness (effectively acting as a healthy control to EHS cases). The prospective quantification of differences between EHS cases and healthy controls could provide insights into useful biomarkers (including markers of kidney, liver, and cardiac injury) to differentiate between patients and aid in the identification and treatment of EHS. The results of this study, therefore, will likely contribute to the identification of EHS-specific biomarkers or biomarker levels (i.e. clinical values) to develop better guidance for prevention, treatment and return-to-duty.
If successful, this work can be followed up by investigating treatments for EHS and their response to biomarkers immediately following hyperthermia and during recovery. Identifying the recovery period for these biomarkers in healthy individuals following high risk events will yield greater knowledge in EHS specific biomarkers and recovery. Follow-on work could also investigate EHS severity and the spectrum of exertional heat injuries to evaluate risk and prognostic factors.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Gabrielle E Giersch, PhD
- Phone Number: 508-206-2421
- Email: gabrielle.e.giersch.civ@health.mil
Study Locations
-
-
Alabama
-
Fort Novosel, Alabama, United States, 36362
- Recruiting
- Fort Novosel
-
-
South Carolina
-
Fort Jackson, South Carolina, United States, 29207
- Not yet recruiting
- Field Study
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals (to include cis- and transgender males and females and nonbinary) 18 years of age or greater
- Current military service (active, Reserve, or National Guard)
- Currently participating in training
Exclusion Criteria:
- Females who are pregnant
- Any individual currently on a physical profile that restricts running or foot marching
- History of obstructive disease of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis.
- Scheduled MRI within 2 weeks after core temp pill ingestion
- Known allergies to skin adhesive
- Blood donation in the past 8 weeks
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Core temperature
Time Frame: Collected only during training, pre-exercisce, post-exercise, and after recovery (from 0-36 hours)
|
Body temperature recorded during training
|
Collected only during training, pre-exercisce, post-exercise, and after recovery (from 0-36 hours)
|
|
Creatinine from blood serum
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Serum creatinine measures to evaluate kidney function
|
Measured at least once every 6 hours for up to 36 hours
|
|
Alanine aminotransferase from blood samples
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Measure of liver function (ALT) from blood
|
Measured at least once every 6 hours for up to 36 hours
|
|
Aspartate aminotransferase (AST)
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Liver function measure (AST) from blood
|
Measured at least once every 6 hours for up to 36 hours
|
|
Heart rate
Time Frame: Measured during training only from start of training up to completion (~4 hours)
|
Heart rate measured during activity
|
Measured during training only from start of training up to completion (~4 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urinary KIM-1
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Measure of kidney function (KIM-1) from urine
|
Measured at least once every 6 hours for up to 36 hours
|
|
Urinary creatinine
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Kidney function measures (creatinine) from urine
|
Measured at least once every 6 hours for up to 36 hours
|
|
Blood sodium concentration
Time Frame: Measured at least once every 6 hours for up to 36 hours
|
Blood sodium concentration
|
Measured at least once every 6 hours for up to 36 hours
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Williams VF, Oh GT. Update: Heat illness, active component, U.S. Armed Forces, 2021. MSMR. 2022 Apr 1;29(4):8-14.
- Roberts WO, Armstrong LE, Sawka MN, Yeargin SW, Heled Y, O'Connor FG. ACSM Expert Consensus Statement on Exertional Heat Illness: Recognition, Management, and Return to Activity. Curr Sports Med Rep. 2021 Sep 1;20(9):470-484. doi: 10.1249/JSR.0000000000000878.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thermoregulation
-
Christopher BellIndiana UniversityCompletedThermoregulationUnited States
-
Old Dominion UniversityCompletedImpaired ThermoregulationUnited States
-
Cardiology Clinical Research & Regulatory GroupCompletedImpaired ThermoregulationUnited States
-
St. Mary's University, TwickenhamNot yet recruitingCaffeine | Thermoregulation
-
Maimonides Medical CenterCompletedImpaired ThermoregulationUnited States
-
McGill UniversityCompletedExercise Performance | Thermoregulation | Cooling FabricsCanada
-
Ulf Dornseifer, MDCompletedMicrocirculation | Thermoregulation | Free FlapGermany
-
Istanbul University - CerrahpasaRecruitingNeonatal Adaptation | Thermoregulation | Neonatal HypothermiaTurkey (Türkiye)
-
University Hospital, Basel, SwitzerlandETH ZurichCompletedThermoregulation ImpairmentSwitzerland
-
University Hospital Schleswig-HolsteinCompletedHypothermia | Postoperative Shivering | Thermoregulation ImpairmentGermany
Clinical Trials on None-placebo
-
Indiana UniversityNot yet recruiting
-
Tarik Emre SenerNot yet recruitingBenign Prostatic Hyperplasia | Bladder Outlet Obstruction | Lower Urinary Tract Symptom
-
Dr. Daniel H. Chang, MDJohnson & Johnson Surgical Vision, Inc.RecruitingVisual Acuity | Posterior Capsule Opacification | Contrast Sensitivity | Visual Function | DysphotopsiaUnited States
-
Xuanwu Hospital, BeijingRecruiting
-
Jesus TorresActive, not recruitingPerformance | Cycling | Iliac Artery Occlusive Disease | Blood Flow VelocitySpain
-
Fujian Medical UniversityActive, not recruitingGastric Adenocarcinoma | Surgery, LaparoscopicChina
-
National Institute of Arthritis and Musculoskeletal...Completed
-
Inversago Pharma Inc.Worldwide Clinical TrialsCompletedDiabetic Kidney DiseaseUnited States, Israel, Canada, Georgia, Hungary, Serbia, Mexico
-
Beijing Tsinghua Chang Gung HospitalRecruitingLiver Cirrhosis | ARDS, Human | Liver Cancer, Adult | Acute Lung Injury(ALI) | NAFLD (Nonalcoholic Fatty Liver Disease) | MASLD | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)China
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingHigh-Risk Acute Myeloid Leukemia | Relapse And/or Refractory AML